Press Releases Novo Nordisk A/S

Equities

NOVO B

DK0062498333

Pharmaceuticals

Market Closed - Nasdaq Copenhagen Other stock markets 09:50:00 17/02/2026 pm IST			5-day change	1st Jan Change
309.90 ^DKK	+0.73%		-1.60%	-4.72%

09:16pm	Dr Reddy's says Wegovy copycat to be priced competitively, with 50-60% discounts feasible	RE
09:00pm	Dr. Reddy's Looks to Launch Generic Wegovy at 60% Discount	MT

Press Releases

07:29pm	Novo Nordisk A/S: The European Commission approves more effective dose of injectable Wegovy® for adults with obesity; clinical study showed people lost about 21% of their body weight on average	GL
12:31pm	Camurus appoints Jane Buus Laursen as Chief Corporate Development Officer	AQ
16/02	Novo Nordisk A/S - share repurchase programme	GL
16/02	FDA Tightens The Belt On GLP-1 Compounding, Escalating Threat Of Enforcement	AQ
14/02	Oral Semaglutide And The GLP-1 Compounding Reckoning: From Regulatory Ambiguity To FDA Enforcement, DOJ Referrals, And Novo Nordisk's Case Against Hims & Hers	AQ
12/02	CEO of Novo Nordisk sees growth potential as Medicare starts reimbursing obesity drugs	AQ
12/02	Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons	GL
11/02	Karolinska Institutet: Molecular patterns behind unstable atherosclerosis identified	AQ
10/02	Patents, Innovation & Where The Law Draws The Line	AQ
10/02	Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons	GL
10/02	Novo Nordisk sues Hims & Hers over copies of Wegovy	AQ
09/02	Novo Nordisk A/S - share repurchase programme	GL
09/02	Novo Nordisk A/S - share repurchase programme	AQ
09/02	Novo Nordisk takes legal action against Hims & Hers to protect patients from unsafe, knock-off Wegovy® and Ozempic®	GL
08/02	Hims & Hers drops plan for knockoff of Novo Nordisk's new Wegovy weight loss pill	AQ
06/02	Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons	GL
06/02	Hims & Hers launches Wegovy knockoff pill, Novo Nordisk vows to sue	AQ
05/02	Novo Nordisk issues statement on illegal mass compounding and deceptive advertising by Hims & Hers	GL
04/02	Blockbuster Weight-Loss and Diabetes Medicines Sales Surge Despite Cost Barriers	AQ
04/02	Novo Nordisk files annual report with the SEC	GL
04/02	Novo Nordisk A/S : Annual Report for Fiscal Year Ending December 31, 2025 (Form 20-F)	PU
04/02	Novo Nordisk: Q4 Earnings Snapshot	AQ
04/02	Novo Nordisk initiates 2026 share repurchase programme	GL
04/02	Novo Nordisk A/S : (novo nordisk annual report 2025)	PU
04/02	Novo Nordisk A/S : (novo nordisk corporate governance report 2025)	PU